NCT03331445View on ClinicalTrials.gov

Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Respiratory Tract InfectionsCorona Virus Infection
Interventions
DRUG

Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation

Inhaled Nitric Oxide 160ppm balance air

Trial Locations (1)

V7H2Y4

Nitric Solutions-Mobile Unit, Vancouver

Sponsors

Collaborators (1)

Mallinckrodt
All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Chris Miller

INDUSTRY